ArticleDiscover oncology2026
Association between molecular subtypes of breast cancer and surgical margin status analysis from Assam, India.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionBreast cancer (BC) is common in young women in India, with 68.8% of cases occurring under 50 years. Key factors regularly evaluated to predict the prognosis and treatment response include tumor size, lymph node, ER, PR, HER2 status, tumor grade, and age. The molecular subtypes Luminal A, Luminal B, HER2- over expressed and triple negative breast cancers carry different treatment plan and prognosis. Regardless of surgical strategy, margin status of the resection specimen remains one of the most important factors of recurrence.
objectiveThis study investigated the association between molecular subtypes and surgical margin status, as well as other prognostic parameters, in women from North Eastern India, where triple negative breast cancer (TNBC) subtype and poor 5-year survival rates are prevalent. METHODOLOGY: This cross-sectional study was conducted at a tertiary care centre in Upper Assam, North East India, from October 2019 to March 2025. BC cases that underwent breast conservative surgery (lumpectomy) or modified radical mastectomy (MRM) and fulfilled the inclusion criteria were included. Tumors were classified into molecular subtypes by immunohistochemistry. Surgical margin status was assessed by histopathological examination, with margins considered positive if neoplastic cells were present at the inked margin. Prognostic parameters with surgical margin status were analyzed using Pearson's Chi-square test and Fisher's exact test.
resultsA total of 155 breast cancer cases were included in the study with average age of 47 years. The distribution of molecular subtypes was: TNBC (36.77%), Luminal A (29.67%), Luminal B (18.06%), and HER2-enriched (15%). Histologic grade III tumors were predominant (58.70%). Total positive margin was 34.83% cases. Positive surgical margins were associated with HER2-enriched subtype (p < 0.05) and grade I tumors. Lymph node involvement was 77%, with stage 2 and 3 accounting for 80.64% of cases.
conclusionOur study highlights the high prevalence of TNBC and the significant association between positive tumor margins and HER2-enriched subtype. The findings emphasize the need for tailored treatment strategies to improve outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.